TY - JOUR
T1 - Pluripotent stem cell derivation and differentiation toward cardiac muscle
T2 - Novel techniques and advances in patent literature
AU - Quattrocelli, Mattia
AU - Thorrez, Lieven
AU - Sampaolesi, Maurilio
PY - 2013
Y1 - 2013
N2 - Pluripotent stem cells hold unprecedented potential for regenerative medicine, disease modeling and drug screening. Embryonic stem cells (ESCs), standard model for pluripotency studies, have been recently flanked by induced pluripotent stem cells (iPSCs). iPSCs are obtained from somatic cells via epigenetic and transcriptional reprogramming, overcoming ESC-related ethical issues and enabling the possibility of donor-matching pluripotent cell lines. Since the European Court of Justice banned patents involving embryo disaggregation to generate human ESCs, iPSCs can now fuel the willingness of European companies to invest in treatments based on stem cells. Moreover, iPSCs share many unique features of ESCs, such as unlimited self-renewal potential and broad differentiation capability, even though iPSCs seem more susceptible to genomic instability and display epigenetic biases as compared to ESCs. Both ESCs and iPSCs have been intensely investigated for cardiomyocyte production and cardiac muscle regeneration, both in human and animal models. In vitro and in vivo studies are continuously expanding and refining this field via genetic manipulation and cell conditioning, trying to achieve standard and reproducible products, eligible for clinical and biopharmaceutical scopes. This review focuses on the recently growing body of patents, concerning technical advances in production, expansion and cardiac differentiation of ESCs and iPSCs
AB - Pluripotent stem cells hold unprecedented potential for regenerative medicine, disease modeling and drug screening. Embryonic stem cells (ESCs), standard model for pluripotency studies, have been recently flanked by induced pluripotent stem cells (iPSCs). iPSCs are obtained from somatic cells via epigenetic and transcriptional reprogramming, overcoming ESC-related ethical issues and enabling the possibility of donor-matching pluripotent cell lines. Since the European Court of Justice banned patents involving embryo disaggregation to generate human ESCs, iPSCs can now fuel the willingness of European companies to invest in treatments based on stem cells. Moreover, iPSCs share many unique features of ESCs, such as unlimited self-renewal potential and broad differentiation capability, even though iPSCs seem more susceptible to genomic instability and display epigenetic biases as compared to ESCs. Both ESCs and iPSCs have been intensely investigated for cardiomyocyte production and cardiac muscle regeneration, both in human and animal models. In vitro and in vivo studies are continuously expanding and refining this field via genetic manipulation and cell conditioning, trying to achieve standard and reproducible products, eligible for clinical and biopharmaceutical scopes. This review focuses on the recently growing body of patents, concerning technical advances in production, expansion and cardiac differentiation of ESCs and iPSCs
KW - Cardiac muscle
KW - Cardiomyocytes
KW - Differentiation
KW - Drug screening
KW - ESCs
KW - IpSCs
KW - Patent literature
KW - Regeneration
UR - http://www.scopus.com/inward/record.url?scp=84873110772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873110772&partnerID=8YFLogxK
U2 - 10.2174/187221113804805883
DO - 10.2174/187221113804805883
M3 - Article
C2 - 22974171
AN - SCOPUS:84873110772
SN - 1872-2113
VL - 7
SP - 18
EP - 28
JO - Recent Patents on Drug Delivery and Formulation
JF - Recent Patents on Drug Delivery and Formulation
IS - 1
ER -